- Home
- SNTG vs RDHL Comparison
SNTG vs RDHL Comparison
Compare SNTG & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- RDHL
- Stock Information
- Founded
- SNTG 2009
- RDHL 2009
- Country
- SNTG China
- RDHL Israel
- Employees
- SNTG N/A
- RDHL N/A
- Industry
- SNTG Finance: Consumer Services
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- RDHL Health Care
- Exchange
- SNTG Nasdaq
- RDHL Nasdaq
- Market Cap
- SNTG 4.8M
- RDHL 3.8M
- IPO Year
- SNTG 2021
- RDHL N/A
- Fundamental
- Price
- SNTG $1.84
- RDHL $1.85
- Analyst Decision
- SNTG
- RDHL
- Analyst Count
- SNTG 0
- RDHL 0
- Target Price
- SNTG N/A
- RDHL N/A
- AVG Volume (30 Days)
- SNTG 6.5K
- RDHL 18.5K
- Earning Date
- SNTG 07-07-2025
- RDHL 04-10-2025
- Dividend Yield
- SNTG N/A
- RDHL N/A
- EPS Growth
- SNTG N/A
- RDHL N/A
- EPS
- SNTG N/A
- RDHL N/A
- Revenue
- SNTG $107,507.00
- RDHL $8,042,999.00
- Revenue This Year
- SNTG N/A
- RDHL $381.91
- Revenue Next Year
- SNTG N/A
- RDHL N/A
- P/E Ratio
- SNTG N/A
- RDHL N/A
- Revenue Growth
- SNTG N/A
- RDHL 23.17
- 52 Week Low
- SNTG $1.43
- RDHL $1.71
- 52 Week High
- SNTG $3.97
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- SNTG 54.53
- RDHL 43.03
- Support Level
- SNTG $1.67
- RDHL $1.72
- Resistance Level
- SNTG $1.92
- RDHL $2.08
- Average True Range (ATR)
- SNTG 0.09
- RDHL 0.09
- MACD
- SNTG 0.01
- RDHL 0.01
- Stochastic Oscillator
- SNTG 62.96
- RDHL 27.78
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.